Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.

Scientific reports - 28 Dec 2022

Margara Francesca, Psaras Yiangos, Wang Zhinuo Jenny, Schmid Manuel, Doste Ruben, Garfinkel Amanda C, Repetti Giuliana G, Seidman Jonathan G, Seidman Christine E, Rodriguez Blanca, Toepfer Christopher N, Bueno-Orovio Alfonso

Abstract excerpt

Cardiomyopathies have unresolved genotype-phenotype relationships and lack disease-specific treatments. Here we provide a framework to identify genotype-specific pathomechanisms and therapeutic targets to accelerate the development of precision medicine. We use human cardiac electromechanical in-silico modelling and simulation which we validate with experimental hiPSC-CM data and modelling in combination with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Cardiomyopathy, Hypertrophic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Congenital heart defects research

Share to Mutation

Share to Myosin Heavy Chains

Share to Precision Medicine

Share to Troponin I

Share to Troponin T

Source

Open in PubMed Open full text

Identifiers

PMID: 36577774
DOI: 10.1038/s41598-022-26889-2
PMCID: PMC9797561

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.PMID 36577774Read ↗

Human iPSC-CMs and in-silico technologies define mechanisms and accelerate targeted pharmacogenetics in hypertrophic cardiomyopathySemantic proximity Read ↗

Altered contractility in mutation-specific hypertrophic cardiomyopathy: a mechano-energetic in silico study with pharmacological insightsSemantic proximity Read ↗

Mechanisms of Pathogenicity of Hypertrophic Cardiomyopathy-Associated Troponin T (TNNT2) Variant R278C <sup>+/-</sup> During DevelopmentSemantic proximity Read ↗

Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathySemantic proximity Read ↗

Harnessing molecular mechanism for precision medicine in dilated cardiomyopathy caused by a mutation in troponin TSemantic proximity Read ↗

Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.Semantic proximity Read ↗

Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contractile machinerySemantic proximity Read ↗

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionSemantic proximity Read ↗

Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatmentSemantic proximity Read ↗

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionSemantic proximity Read ↗

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.Semantic proximity Read ↗

Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.